| Co-Investigator(Kenkyū-buntansha) |
HARA Akira 岐阜大学, 大学院・医学系研究科, 教授 (10242728)
KATO Keizou 岐阜大学, 医学部附属病院, 講師 (40397336)
MAKITA Hiroki 岐阜大学, 大学院・医学系研究科, 講師 (50345790)
宮崎 康雄 岐阜大学, 医学部附属病院, 医員 (60509818)
山下 知巳 岐阜大学, 医学部附属病院, 准教授 (80345793)
|
|---|
| Budget Amount *help |
¥15,730,000 (Direct Cost: ¥12,100,000、Indirect Cost: ¥3,630,000)
Fiscal Year 2013: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2012: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2011: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2010: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2009: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Research Abstract |
To reveal the effects of DNA methylation status on the oral cancer carcinogenesis, we carried out the analysis of lesions in in betel quid chewers. First of all, we evaluated the swab sample accuracy using swab and tissue samples in promoter region of p16 and MGMT so on. DNA methylation status was well correlated between swab and tissue samples. Then, we analyzed DNA methylation status of Taiwan swab samples using pyrosequencing method focused on p16 and MGMT. 10% samples indicated positive. Furthermore, we examined the methylation positive of p16 in cancer patients and detected it in high ratio (almost 100%). These results possibly suggested the usefulness of p16 analysis as a biomarker in oral cancer.
|
